Patents by Inventor Antony A. Cooper

Antony A. Cooper has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modulators of alpha-synuclein toxicity
    Patent number: 10526651
    Abstract: Disclosed are compositions and methods for modulating expression of genes that function at the step of ER to Golgi trafficking. Compounds that modulate expression of these genes or activity of the encoded proteins can be used to inhibit alpha-synuclein mediated toxicity and used to treat or prevent synucleinopathies such as Parkinson's disease. Also disclosed are methods of identifying inhibitors of alpha-synuclein mediated toxicity.
    Type: Grant
    Filed: January 18, 2013
    Date of Patent: January 7, 2020
    Assignees: Whitehead Institute for Biomedical Research, The Curators of the University of Missouri
    Inventors: Susan L. Lindquist, Aaron D. Gitler, Anil Cashikar, Antony A. Cooper, Cole M. Haynes
  • Modulators of alpha-synuclein toxicity
    Patent number: 8399241
    Abstract: Disclosed are compositions and methods for modulating expression of genes that function at the step of ER of Golgi trafficking. Compounds that modulate expression of these genes of activity of the encoded proteins can be used to inhibit alpha-synuclein mediated toxicity and used to threat of prevent synucleinopathies such as Parkinson's disease. Also disclosed are methods of identifying inhibitors of alpha-synuclein mediated toxicity.
    Type: Grant
    Filed: December 1, 2005
    Date of Patent: March 19, 2013
    Assignees: Whitehead Institute for Biomedical Research, The Curators of the University of Missouri
    Inventors: Susan L. Lindquist, Aaron D. Gitler, Anil Cashikar, Antony A. Cooper, Cole M. Haynes
  • MODULATORS OF ALPHA-SYNUCLEIN TOXICITY
    Publication number: 20090099069
    Abstract: Disclosed are compositions and methods for modulating expression of genes that function at the step of ER of Golgi trafficking. Compounds that modulate expression of these genes of activity of the encoded proteins can be used to inhibit alpha-synuclein mediated toxicity and used to threat of prevent synucleinopathies such as Parkinson's disease. Also disclosed are methods of identifying inhibitors of alpha-synuclein mediated toxicity.
    Type: Application
    Filed: December 1, 2005
    Publication date: April 16, 2009
    Applicants: WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH, THE CURATORS OF THE UNIVERSITY MISSOURI
    Inventors: Susan L. Lindquist, Aaron D. Gitler, Anil Cashikar, Antony A. Cooper, Cole M. Haynes